Product Images Gabapentin

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 6 images provide visual information about the product associated with Gabapentin NDC 70518-3759 by Remedyrepack Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Remedy_Label - Remedy Label

Remedy_Label - Remedy Label

This is a description for the medication Gabapentin. It is a capsule containing 400 mg of the active ingredient. The prescription is for a quantity of 30 capsules. The medication is only available through a prescription (RX ONLY). The medication is made by Sun Pharma, located in Cranbury, NJ. The National Drug Code (NDC) for this medication is 70518-3759-00. The expiration date and lot number are not provided in the text. The source NDC, which may refer to the original manufacturer, is 62756-0139-02. The medication should be stored between 20-25°C (88-77°F) with excursions permitted between 15-30°C (59-86°F). The medication has been repackaged by RemedyRepack Inc. located in Indiana, PA. Their contact number is 724.465.8762.*

spl-gabapentin-figure1 - spl gabapentin figure1

spl-gabapentin-figure1 - spl gabapentin figure1

The description is not available.*

spl-gabapentin-figure2 - spl gabapentin figure2

spl-gabapentin-figure2 - spl gabapentin figure2

This text provides information about a study evaluating the mean pain scores over a period of time. The study consists of a 3-week dose titration period, followed by a 4-week fixed dose period. The text mentions three treatment groups: placebo, gabapentin at a dose of 1,800 mg/day, and gabapentin at a dose of 2,400 mg/day. The text also includes a figure showing the weekly mean pain scores observed in the ITT population for Study 2.*

spl-gabapentin-figure3 - spl gabapentin figure3

spl-gabapentin-figure3 - spl gabapentin figure3

The text provides a visual representation of the proportion of responders in controlled studies for patients with greater than 50% reduction in pain score in postherpetic neuralgia (PHN). The figure shows the percentages of responders at endpoint for two studies (Study 1 and Study 2) with data represented in a bar graph. It also mentions statistical significance indicated by p-values. The specific numbers mentioned at the end (3,600, 1,800, 2,400) are not clear.*

spl-gabapentin-figure4 - spl gabapentin figure4

spl-gabapentin-figure4 - spl gabapentin figure4

SPL - spl gabapentin structure

SPL - spl gabapentin structure

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.